Completed PHASE1 INTERVENTIONAL 2-arm NCT01503398

Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions

An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Olanzapine Tablets 5 mg With Zyprexa® Tablets 5 mg in Healthy Subjects Under Fasting Conditions

Sponsor: Dr. Reddy's Laboratories Limited

Conditions Fasting

Interventions Olanzapine

Updated 6 times since 2017 Last updated: Jan 4, 2012 Started: Aug 31, 2011 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01503398, this PHASE1 trial focuses on Fasting and remains completed. Sponsored by Dr. Reddy's Laboratories Limited, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Reddy's Laboratories Limited

Data source: Dr. Reddy's Laboratories Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ahmedabad, India